KDM6B and osteosarcoma: Furthermore, JMJD3+/VEGFR2+ cell subset was found in more chemotherapy-resistant osteosarcoma tumors (n = 6), and the proportion of JMJD3+/VEGFR2+ double-positive cells was more than 20% in these samples (Fig. 1g).